HC Wainwright Issues Positive Outlook for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Equities research analysts at HC Wainwright increased their Q2 2026 EPS estimates for Unicycive Therapeutics in a research note issued to investors on Wednesday, May 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.27) for the quarter, up from their previous forecast of ($0.28). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.44) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($1.04) EPS, Q1 2027 earnings at $0.26 EPS, Q2 2027 earnings at $0.35 EPS, Q3 2027 earnings at $0.46 EPS and Q4 2027 earnings at $0.51 EPS.

Several other brokerages have also recently commented on UNCY. Benchmark lowered their target price on shares of Unicycive Therapeutics from $21.00 to $15.00 and set a “speculative buy” rating on the stock in a report on Monday, April 6th. B. Riley Financial began coverage on shares of Unicycive Therapeutics in a report on Friday, May 1st. They set a “buy” rating and a $22.00 target price on the stock. Guggenheim reaffirmed a “buy” rating and set a $37.00 target price (down from $40.00) on shares of Unicycive Therapeutics in a report on Wednesday. Wall Street Zen cut shares of Unicycive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 2nd. Finally, Westpark Capital began coverage on shares of Unicycive Therapeutics in a report on Thursday, February 19th. They set a “buy” rating on the stock. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Unicycive Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $24.00.

Unicycive Therapeutics Stock Up 0.6%

Shares of UNCY stock opened at $8.56 on Friday. The firm has a 50 day moving average price of $7.10 and a two-hundred day moving average price of $6.38. The company has a market capitalization of $228.55 million, a PE ratio of -3.87 and a beta of 1.78. Unicycive Therapeutics has a 12-month low of $3.71 and a 12-month high of $11.00.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.08).

Institutional Trading of Unicycive Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of UNCY. Lazard Asset Management LLC bought a new stake in shares of Unicycive Therapeutics during the second quarter worth $55,000. JPMorgan Chase & Co. grew its stake in shares of Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after buying an additional 21,525 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Unicycive Therapeutics during the first quarter worth $161,000. Citadel Advisors LLC bought a new stake in shares of Unicycive Therapeutics during the third quarter worth $182,000. Finally, Quadrature Capital Ltd bought a new stake in shares of Unicycive Therapeutics during the fourth quarter worth $226,000. Institutional investors own 40.42% of the company’s stock.

Key Stories Impacting Unicycive Therapeutics

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Noble Financial raised its FY2026 EPS estimate to $1.46 from $0.85 and boosted its Q3 2026 view to $1.32 from $0.79, suggesting improved longer-term profitability expectations.
• Positive Sentiment: HC Wainwright slightly improved its Q2 2026 EPS estimate to ($0.27) from ($0.28), and trimmed its Q4 2026 loss estimate to ($0.03) from ($0.12), indicating a modestly better near-term outlook.
• Positive Sentiment: HC Wainwright also lifted its Q1 2027, Q2 2027, Q3 2027, and Q4 2027 EPS estimates, pointing to stronger profitability later in the forecast period.
• Neutral Sentiment: Analyst reports from HC Wainwright and Noble Financial updated multiple quarterly earnings estimates for UNCY, but the company’s consensus full-year outlook remains a loss at ($1.44) per share.
• Negative Sentiment: HC Wainwright cut its FY2026 EPS estimate to ($1.04) from ($0.90), implying a larger expected loss for the current year. HC Wainwright FY2026 estimate cut
• Negative Sentiment: Noble Financial lowered its Q2 2026 EPS estimate to ($0.77) from ($0.52), and HC Wainwright cut its Q3 2026 estimate to ($0.20) from ($0.16), reinforcing some near-term pressure on earnings expectations.
• Negative Sentiment: Separate headlines noted a reduced price target and a “pivots from profit to loss” narrative, which could contribute to bearish sentiment around the stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.